Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2.
Radioimmunoimaging of xenograft pancreatic cancer with 131I-monoclonal antibody P2.
复制标题
使用 131I-单克隆抗体 P2 对异种移植胰腺癌进行放射免疫成像。
DOI：
10.1097/00006676-199305000-00002
复制
发表时间：
1993
期刊：
影响因子：
2.9
通讯作者：
Thompson,JC
中科院分区：
文献类型：
--
作者：
Yao,CZ;Poston,GJ;Ishizuka,J;TownsendJr,CM;Thompson,JC
Monoclonal antibodies (McAbs) to pancreatic cancer were developed by fusing SP2/0 cells and splenocytes from Balb/c mice immunized with CH-2 cells. The specific binding rates of McAb PI and P2 were 40.1 and 43.8%, respectively, shown by binding radioreactivity assay in vitro, which were in sharp contrast with those of control groups (p< 0.05). The biodistribution of radioiodinated McAb P2 was studied by measuring parameters of tumor-specific radioreactivity in nude mice bearing CH-2 tumors. The ratios of tumors to nontumors were all> 2 at 48 h. The localization index of cancer and the ratio of tumor to pancreas were 4.05 and 4.16, respectively, at 72 h. Therefore,'311-McAbs may be useful for radioimmunoimaging (RII) of pancreatic cancer. After intraperitoneal injection of 131 I-McAb P2 into tumor-bearing nude mice, imaging of xenograft pancreatic cancer became increasingly distinct with the nonspecific background fading, especially in the period of 72–96 h. Examination of pancreatic cancer tissues by immunohistochemical methods revealed that McAb P2 was strongly positive (86%) in comparison with other tumors and normal tissues. The results demonstrated that clinical RII of pancreatic cancer was feasible with McAb P2.
